Results 31 to 40 of about 12,380 (194)

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications.

PLoS ONE, 2023
Background and purposeProphylactic prasugrel for endovascular treatment of intracranial aneurysms has been introduced and increased, but HTPR (high on-treatment platelet reactivity) or LTPR (low on-treatment platelet reactivity) of prasugrel is not ...
Noah Hong, Seung Bin Kim, Hee-Jin Yang, Young-Je Son   +3 more
doaj   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

P‐CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with atherothrombotic disease on antithrombotic therapy, P‐CABs demonstrated a significantly superior protective effect against clinically significant upper GI haemorrhage compared to PPIs (aHR 0.22; p = 0.016). This real‐world study highlights P‐CABs as a more potent gastroprotective strategy for high‐risk populations requiring intensive ...
Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae   +6 more
wiley   +1 more source

Prasugrel, ein neues Thienopyridin

, 2007
ZusammenfassungMit Einführung der Thienopyridine, insbesondere des Clopidogrels, standen erstmals oral wirksame therapeutische Alternativen zu Azetylsalizylsäure (ASS) als Antiplättchensubstanzen zur Verfügung.
K. Schrör, K. Huber
core   +1 more source

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Journal of Hematology & Oncology, 2013
Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD ...
Wun Ted, Soulieres Denis, Frelinger Andrew L, Krishnamurti Lakshmanan, Novelli Enrico M, Kutlar Abdullah, Ataga Kenneth I, Knupp Charles L, McMahon Lillian E, Strouse John J, Zhou Chunmei, Heath Lori E, Nwachuku Chuke E, Jakubowski Joseph A, Riesmeyer Jeffrey S, Winters Kenneth J   +15 more
doaj   +1 more source

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis

Frontiers in Cardiovascular Medicine, 2022
BackgroundThis meta-analysis mainly aimed to compare the impact of prasugrel and ticagrelor on platelet reactivity (PR) in patients with acute coronary syndrome (ACS).MethodsWe searched four electronic databases to identify randomized controlled trials ...
Lulu Dai, Jiawei Xu, Yuerong Jiang, Keji Chen   +3 more
doaj   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, EarlyView.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

Prasugrel Metabolites Inhibit Neutrophil Functions s [PDF]

, 2020
Clopidogrel and prasugrel belong to a thienopyridine class of oral antiplatelet drugs that, after having been metabolized in the liver, can inhibit platelet function by irreversibly antagonizing the P2Y 12 receptor. Furthermore, thienopyridines influence
S P K ), L E K, Satya P Kunapuli, Laurie E Kilpatrick, Elisabetta Liverani, Mario C Rico, Analia E Garcia   +6 more
core  

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
Background Few studies have examined how antiplatelet therapies are selected during the routine care of acute myocardial infarction patients, particularly relative to the patient's estimated mortality and bleeding risks.
Amit N. Vora, Eric D. Peterson, Lisa A. McCoy, Mark B. Effron, Kevin J. Anstrom, Douglas E. Faries, Marjorie E. Zettler, Gregg C. Fonarow, Brian A. Baker, Gregg W. Stone, Tracy Y. Wang   +10 more
doaj   +1 more source

PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM

Атеротромбоз, 2018
Prasugrel is a third-generation thienopyridine that provides earlier onset of action, has a reduced probability of insensitivity to the drug, a greater degree of inhibition of ADP-induced platelet aggregation compared to clopidogrel.
O. O.  Shakhmatova, A. L. Komarov
doaj   +1 more source